Vosaroxin

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Vosaroxin
Accession Number
DB11999
Description

Vosaroxin is under investigation for the treatment of Leukemia, Myeloid, Acute.

Type
Small Molecule
Groups
Investigational
Structure
Thumb
Weight
Average: 401.44
Monoisotopic: 401.115775286
Chemical Formula
C18H19N5O4S
Synonyms
  • Voreloxin
External IDs
  • AG-7352
  • SNS-595
  • SPC-595

Pharmacology

Indication
Not Available
Contraindications & Blackbox Warnings
Learn about our commercial Contraindications & Blackbox Warnings data.
Learn More
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half-life
Not Available
Clearance
Not Available
Adverse Effects
Learn about our commercial Adverse Effects data.
Learn More
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
Darbepoetin alfaThe risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Vosaroxin.
ErythropoietinThe risk or severity of Thrombosis can be increased when Erythropoietin is combined with Vosaroxin.
Methoxy polyethylene glycol-epoetin betaThe risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Vosaroxin.
PeginesatideThe risk or severity of Thrombosis can be increased when Peginesatide is combined with Vosaroxin.
Additional Data Available
  • Extended Description
    Extended Description

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
Not Available

Products

Categories

ATC Codes
L01XX53 — Vosaroxin
Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as naphthyridine carboxylic acids and derivatives. These are compounds containing a naphthyridine moiety, where one of the ring atoms bears a carboxylic acid group.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Diazanaphthalenes
Sub Class
Naphthyridines
Direct Parent
Naphthyridine carboxylic acids and derivatives
Alternative Parents
Pyridinecarboxylic acids / Dialkylarylamines / Aminopyridines and derivatives / Imidolactams / Vinylogous amides / Thiazoles / Pyrrolidines / Heteroaromatic compounds / Amino acids / Dialkylamines
show 5 more
Substituents
Amine / Amino acid / Amino acid or derivatives / Aminopyridine / Aromatic heteropolycyclic compound / Azacycle / Azole / Carboxylic acid / Carboxylic acid derivative / Dialkyl ether
show 19 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
Not Available

Chemical Identifiers

UNII
K6A90IIZ19
CAS number
175414-77-4
InChI Key
XZAFZXJXZHRNAQ-STQMWFEESA-N
InChI
InChI=1S/C18H19N5O4S/c1-19-12-8-22(9-13(12)27-2)14-4-3-10-15(24)11(17(25)26)7-23(16(10)21-14)18-20-5-6-28-18/h3-7,12-13,19H,8-9H2,1-2H3,(H,25,26)/t12-,13-/m0/s1
IUPAC Name
7-[(3S,4S)-3-methoxy-4-(methylamino)pyrrolidin-1-yl]-4-oxo-1-(1,3-thiazol-2-yl)-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid
SMILES
CN[[email protected]]1CN(C[[email protected]@H]1OC)C1=CC=C2C(=O)C(=CN(C3=NC=CS3)C2=N1)C(O)=O

References

General References
Not Available
PubChem Compound
9952884
PubChem Substance
347828318
ChemSpider
8128494
ChEMBL
CHEMBL68117
ZINC
ZINC000026186622
Wikipedia
Vosaroxin

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
3CompletedTreatmentAcute Myeloid Leukemia (AML) / Acute Nonlymphocytic Leukemia / Leukemias1
2Active Not RecruitingTreatmentAcute Myeloid Leukemia (AML) / Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome / Acute Myeloid Leukemia With Multilineage Dysplasia / Granulocytic Sarcoma / Secondary Acute Myeloid Leukemia (Secondary AML, sAML) / Therapy-Related Acute Myeloid Leukemia / Therapy-Related Myelodysplastic Syndrome1
2CompletedTreatmentAcute Disease / Acute Myeloid Leukemia (AML) / Leukemias / Myelodysplastic Syndromes (MDS) / Nonlymphocytic Leukemia1
2CompletedTreatmentCarcinoma, Small Cell / Small Cell Lung Cancer (SCLC)1
2CompletedTreatmentNon-Small Cell Lung Carcinoma (NSCLC)1
2CompletedTreatmentOvarian Epithelial Cancer1
2RecruitingTreatmentAcute Myeloid Leukemia (AML) / Myelodysplastic Syndrome With Excess Blasts-2 (MDS-EB-2)1
2, 3RecruitingTreatmentAcute Myeloid Leukemia (AML)1
2, 3RecruitingTreatmentAcute Myeloid Leukemia (AML) / Myelodysplastic Syndrome1
1Active Not RecruitingTreatmentMyelodysplastic Syndromes (MDS)1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.128 mg/mLALOGPS
logP-0.49ALOGPS
logP-0.42ChemAxon
logS-3.5ALOGPS
pKa (Strongest Acidic)5.06ChemAxon
pKa (Strongest Basic)8.8ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count9ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area107.89 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity103 m3·mol-1ChemAxon
Polarizability41.3 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Drug created on October 20, 2016 15:09 / Updated on June 12, 2020 10:53

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates